> Detailanzeige

Nickolls, Sarah A; Gurrell, Rachel; van Amerongen, Guido; Kammonen, Juha; Cao, Lishuang; Brown, Adam R; Stead, Clara; Mead, Andy; Watson, Christine; Hsu, Cathleen; Owen, Robert M; Pike, Andy; Fish, Rebecca L; Chen, Laigao; Qiu, Ruolun; Morris, Evan D; Feng, Gang; Whitlock, Mark; Gorman, Donal; van Gerven, Joop; Reynolds, David S; Dua, Pinky; Butt, Richard P

Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF‐06372865

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF‐06372865
  • Beteiligte: Nickolls, Sarah A; Gurrell, Rachel; van Amerongen, Guido; Kammonen, Juha; Cao, Lishuang; Brown, Adam R; Stead, Clara; Mead, Andy; Watson, Christine; Hsu, Cathleen; Owen, Robert M; Pike, Andy; Fish, Rebecca L; Chen, Laigao; Qiu, Ruolun; Morris, Evan D; Feng, Gang; Whitlock, Mark; Gorman, Donal; van Gerven, Joop; Reynolds, David S; Dua, Pinky; Butt, Richard P
  • Erschienen: Wiley, 2018
  • Erschienen in: British Journal of Pharmacology, 175 (2018) 4, Seite 708-725
  • Sprache: Englisch
  • DOI: 10.1111/bph.14119
  • ISSN: 0007-1188; 1476-5381
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Background and PurposeBenzodiazepines, non‐selective positive allosteric modulators (PAMs) of GABAA receptors, have significant side effects that limit their clinical utility. As many of these side effects are mediated by the α1 subunit, there has been a concerted effort to develop α2/3 subtype‐selective PAMs.Experimental ApproachIn vitro screening assays were used to identify molecules with functional selectivity for receptors containing α2/3 subunits over those containing α1 subunits. In vivo receptor occupancy (RO) was conducted, prior to confirmation of in vivo α2/3 and α1 pharmacology through quantitative EEG (qEEG) beta frequency and zolpidem drug discrimination in rats respectively. PF‐06372865 was then progressed to Phase 1 clinical trials.Key ResultsPF‐06372865 exhibited functional selectivity for those receptors containing α2/3/5 subunits, with significant positive allosteric modulation (90–140%) but negligible activity (≤20%) at GABAA receptors containing α1 subunits. PF‐06372865 exhibited concentration‐dependent occupancy of GABAA receptors in preclinical species. There was an occupancy‐dependent increase in qEEG beta frequency and no generalization to a GABAA α1 cue in the drug‐discrimination assay, clearly demonstrating the lack of modulation at the GABAA receptors containing an α1 subtype. In a Phase 1 single ascending dose study in healthy volunteers, evaluation of the pharmacodynamics of PF‐06372865 demonstrated a robust increase in saccadic peak velocity (a marker of α2/3 pharmacology), increases in beta frequency qEEG and a slight saturating increase in body sway.Conclusions and ImplicationsPF‐06372865 has a unique clinical pharmacology profile and a highly predictive translational data package from preclinical species to the clinical setting.
  • Zugangsstatus: Freier Zugang